PHT-427 (CS-0223) is a dual inhibitor of Akt and PDPK1 with a high affinity for the PH domain of Akt and PDPK1 with Ki of 2.7 μM and 5.2 μM, respectively.

 

Brand: BCM

 

Target: Apoptosis; Akt; PDK

 

Signaling Pathways: Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling

 

In Vitro: When BxPC-3 was treated with PHT-427 (125-250 mg/kg), the tumor growth inhibition rate reached 80%. PHT-427 showed significant anti-tumor activity in BxPC-3 pancreatic cancer, MCF-7 breast cancer and A-549 NSCL cancer xenografts.

 

Melting Point: 126-127 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))

 

Boiling Point: 535.0±43.0 °C(Predicted)

 

pKa: 6.03±0.40(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC2=NN=CS2  

 

InChIKey: BYWWNRBKPCPJMG-UHFFFAOYSA-N  

 

InChI: InChI=1S/C20H31N3O2S2/c1-2-3-4-5-6-7-8-9-10-11-12-18-13-15-19(16-14-18)27(24,25)23-20-22-21-17-26-20/h13-17H,2-12H2,1H3,(H,22,23)

 

Attribute
[Chem Name]	4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
[Synonym]	PHT-427; CS-0223
[CAS No.]	1191951-57-1
[MDL No.]	MFCD18384970
[Formula]	C20H31N3O2S2
[Molecular]	409.61
[Form]	White solid
[Storage]	Keep in dark place. Inert atmosphere. Room temperature

Goods Tag